Consistent with this, an analysis of 134 stage II/III GC patients receiving S-1 adjuvant chemotherapy associated higher TNS4 expression with poorer 5-year survival [132], while IHC of 80 cases linked upregulated protein levels to disease progression and poor prognosis [133]. Here, TNS4 is linked to gastric cancer.